Proposed fed law could lower drug prices for Americans

Arizona Capitol Times | December 27, 2019

Impeachment may be the only thing on the news these days, but it’s certainly not the only thing happening in Congress. On Dec. 12, the U.S. House passed H.R. 3 , the Lower Drug Costs Now Act. This is the most significant stand-alone prescription drug bill to pass either chamber of Congress since 2003. In a nutshell, the Lower Drug Costs Now Act gives Medicare the power to negotiate directly with pharmaceutical companies to bring down the price of some of the most heavily purchased medications in the United States. Medicare is the largest customer of prescription drugs in the country, serving 59 million seniors and people with disabilities, including 1.2 million here in Arizona. Unfortunately, pharmaceutical companies have effectively banned Medicare from negotiating lower prices. Any good business would look to negotiate lower costs because they buy in such volume, but Congress has made that impossible. Under this reform, that will change.

Spotlight

Measurements and characterization of binding interactions between proteins and low-molecular weight ligands are fundamental for drug discovery. Among the most recognized challenges in characterizing binding interactions are (1) the need to accurately assess a wide span of binding affinities (KD) and (2) accurately rank and characterize low-molecular weight (LMW) ligands based on affinity, mechanism of action, and energetics of interaction.

Spotlight

Measurements and characterization of binding interactions between proteins and low-molecular weight ligands are fundamental for drug discovery. Among the most recognized challenges in characterizing binding interactions are (1) the need to accurately assess a wide span of binding affinities (KD) and (2) accurately rank and characterize low-molecular weight (LMW) ligands based on affinity, mechanism of action, and energetics of interaction.

Related News

PHARMA TECH

CPhI partners with Informa Pharma Intelligence to present the 2021 Hybrid Edition of CPhI - P-MEC Expo in the National Capital Region ( NCR)

Informa Pharma Intelligence | November 26, 2021

Informa Pharma Intelligence, one of the leading business intelligence providers and knowledge partners, is pleased to announce the 2021 hybrid edition of CPhI – P-MEC conducted by CPhI Conference. The Online Conference & Networking is being held between 15th to 30th Nov 2021, while the In-Person event is being held between 24th to 26th Nov 2021 at India Expo Centre– Greater Noida, Delhi. In a bid to stay afloat towards increasing contemporary demand towards high quality, low cost pharma solutions, CPhI & P_MEC India has curated a platform through this event for a gateway to latest trends and innovative solutions that the market has to offer. The event aims to build better pharma community engagements, network amongst the fraternity and source innovative solutions on-site from exhibitors who have footprints both domestically and globally, and covering the entire pharma supply chain - from APIs, machinery, technology, packaging, outsourcing, finished products and biopharmaceuticals. The industry is anticipated to have a steady growth trajectory and the event organised by CHhI India has focused on the key driving factors for the same. The expansion of medicine manufacturing pertaining to the evolving epidemiological profile of the country will be instrumental for India being the preferred drug manufacturing destination on a global scale. Additionally the event aims to encourage the development of the research-based pharma fraternity. "The Indian pharmaceutical industry has been growing at double digits year-on-year, and remains committed to not only providing solutions to the healthcare needs of the country, but also to the world. As the world is battling the pandemic at different levels, here in India, we remain committed to ramping up production capabilities of some key medicines across infectious and non-infectious diseases to ensure their availability and accessibility to the country and the world. The CPhI – P-MEC India show is the single location for all pharmaceutical and allied companies to get together and share insights, techniques and technology that will help meet these demands." Speaking at the sidelines of the CPhI – P-MEC India show, Mr Yogesh Mudras, Managing Director, Informa Markets in India As a part of the management team of the CPhI – P-MEC 2021 event, Mr Poornachandra Tejasvi, Senior Director, Emerging Markets, India, at Informa Pharma Intelligence said, "As a representative of the world's leading pharmaceutical business intelligence provider, its heart-warming to be a part of the CPhI – P-MEC event where we get to share meaningful insights drawn from real-time news, trends, market analysis, special reports, to key pharmaceutical companies in the country and the world. Globally we provide intelligence to over 10,000 customers and 3,000 of the top pharma, biotech and biosimilar companies with the collective support of more than 300 respected Business Intelligence subject matter analysts, editors, and thought leaders located across countries. The 2021 CPhI – P-MEC event will be a great opportunity to reconnect with the stakeholders of the pharmaceutical world and provide them with any form of data intelligence and analysis as needed." The Indian pharmaceutical market is growing at 15% annually, twice the world market growth rate. While its generics market is growing strong, it is also evolving into a cradle for new drugs. Therefore, with India being one of the strongest emerging markets in the global pharma industry, it presents great opportunities for all international pharmaceutical companies to explore, the platform by CPhI & P-MEC provides full access to the exhibitors to source new pharma solutions and find the right partners for your business with the ongoing hybrid expo showcasing the full drug development supply-chain from exporting, outsourcing, manufacturing, machinery, regulations, pricing, and market access to, packaging, labelling, and digitalization. The P-MEC event is the single destination in the country today for all things associated with the latest innovative pharma solutions that the world has to offer. The venue will also host the latest types of equipment associated with research and development and analytical solutions followed by cleanroom engineering design, certifications and the latest types of air purification solutions. The packaging technology on display will include a comprehensive range of glass, pouches, bottles, caps, tubes and plastic packages as well as printing and trademark solutions. CPhI India is a sister brand of CPhI Worldwide – A key event that all professionals from the international pharmaceutical and allied industries look forward to year on year. CPhI India and its co-located event, P-mec India, are the largest and most comprehensive pharmaceutical industry events in South Asia. This event is specifically important to the country as India is already labelled as the pharmacy of the world in addition to the vaccine manufacturing prowess showcased in 2019-2020. About Informa Pharma Intelligence Trusted by over 3,000 of the world's leading pharmaceutical, biotech, medical device companies, and CROs, the Pharma Intelligence suite of intelligence solutions, which include Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™, deliver vital, accurate, and timely intelligence and analysis about the drug development pipeline to pharmaceutical and biomedical decision makers around the world. A global team of subject area experts track and analyse key diseases, clinical trials, drug approvals and R&D activities, to deliver data needed to make decisions and create real-world opportunities for growth. About CPhI Conferences The world's largest pharmaceutical exhibition, CPhI Worldwide represents every stage of the pharmaceutical supply chain - from ingredients and FDF, to machinery, packaging, outsourcing and biopharmaceuticals. Each year the CPhI brand unites more than 100,000 pharmaceutical professionals from all over the world through exhibitions, conferences and online communities. CPhI offers healthcare experts a chance to network, identify business opportunities and expand the global market through online and in-person interactions, with events in Europe, China, Korea, India, Japan, Southeast Asia and North America.

Read More

PHARMACY MARKET

Novartis' Sandoz spotlights importance of generic drugs in new social campaign

Novartis | December 17, 2020

Did you realize that 90% of remedies are composed for nonexclusive medications? Novartis' Sandoz is getting the news out about nonexclusive medication with such realities in its as of late dispatched "Request Generics" crusade. It's Sandoz's first significant instruction and mindfulness crusade via online media to advance the estimation of generics. The intended interest group is key partners—patients, clinicians, policymakers and payers—with messages running on LinkedIn and Twitter. Sandoz plans to run the mission through the finish of the principal quarter, perhaps more, contingent upon results. It's as of now chipping away at a second stage that will move center to biosimilar adaptations of marked biologic medications. "Generics are assuming a truly significant job, and I believe it's ideal planning currently to discuss the significant job generics play in a well-working medical care framework," said Carol Lynch, Sandoz's U.S. president and head of North America. Other than featuring the pervasiveness of generics, the online media posts promote their reasonableness and their status as firmly directed items—as protected and powerful as their image name partners. The moderateness and security messages are significant, alongside the general token of the opposition generics give in the commercial center. The duplicates of costlier marked medications help to make "a sound serious market that is directed to patients having expanded admittance to the prescriptions they need," Lynch said. Nonexclusive medications saved the U.S. medical services framework $313 billion a year ago, as per the 2020 yearly report of conventional and biosimilar access and reserve funds in the U.S. from the Association for Accessible Medicines, a generics industry exchange gathering.

Read More

PHARMA TECH

Capacity and Citeline Connect Partner for AI-Powered Clinical Trial Recruitment Experience

Capacity | August 12, 2021

Capacity, an AI-powered support automation platform, today announces its partnership with Citeline Connect, the all-in-one clinical trial recruitment platform developed by Informa Pharma Intelligence. The companies partnered to launch Moderna's clinical trial recruitment website with an AI-powered chatbot to provide a comprehensive experience for potential study participants. This partnership enables customers like Moderna to create engaging clinical trial recruitment websites. With the power of Capacity's chatbot and support automation software alongside Citeline Connect technology, users are able to actively complete registration and pre-screening through an easy-to-use interface. "Our work with Citeline Connect is reflective of our ultimate goal at Capacity, leveraging a company's existing knowledge base with support automation to help teams do their best work," said David Karandish, CEO of Capacity. "As we see relief from the COVID-19 pandemic on the horizon, there is still a way to go before we are in the clear. In working with Citeline Connect, we're honored to have the opportunity to provide helpful technology for healthcare providers, researchers, and patients." Capacity and Citeline Connect's first-of-its-kind work will enhance the patient experience. With user-friendly technology, Capacity's chatbot provides an expansive knowledge-base and user-friendly solution. "We are proud of our ability to create more opportunities for the public to engage with important clinical trials," said Chris Venezia, chief commercial officer at Citeline Connect. "Working with Capacity is a no-brainer to provide an extensive solution that meets the needs of potential patients and the clinical trial sponsors. They make it easy for both potential and current study participants to ask questions, find clinical trial information, and begin their study enrollment journey" This partnership comes on the heels of Capacity's growth and recognition across industries. Capacity was recognized as the "Adaptive Learning Innovation of the Year" in the 2021 EdTech Breakthrough Awards, as a "Tech 100 Mortgage Winner" by HousingWire, and was a 2021 FinTech award winner for the "Most Innovative Financial Services Machine Learning UI Solution - North America" by Wealth and Finance International. Capacity was also recognized by Knowledge Management World as one of the top 100 companies that matter most in knowledge management, and secured $12M in Series C funding late last year to continue innovating solutions for its customers. About Capacity Capacity is an AI-powered support automation platform that connects your entire tech stack to answer questions, automate repetitive support tasks, and build solutions to any business challenge. Capacity was founded in 2017 by David Karandish and Chris Sims, and is part of the Equity.com incubator.

Read More